医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Optibrium and Bugworks Sign Agreement for StarDrop License

2017年07月25日 PM05:43
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, United Kingdom & BENGALURU, India

Optibrium™, a developer of software for small molecule discovery, and Bugworks Research Inc. (Bugworks), a company focused on discovering biopharmaceuticals for the treatment of critical and serious bacterial infections, today announced the signing of a two-year agreement to license Optibrium’s StarDrop™ software. The agreement will see deployment of StarDrop and five of its plug-in modules enabling Bugworks’ scientists at their research site in India to quickly understand structure-activity relationships, identify potential liabilities and design new compounds with the highest chance of success.

Dr V. Balasubramanian, President R&D of Bugworks commented: “The antibiotic pipeline lacks new mechanisms against drug resistant Gram-negative bacteria. Our own in-house efforts to address this are complemented by StarDrop’s intuitive user interface and unique approach to multi-parameter optimisation and compound design.”

Nick Foster, Optibrium’s Head of Commercial Operations, added: “We are delighted to welcome Bugworks to the family of StarDrop users. Antibiotic resistance is a growing global concern and we look forward to supporting the use of StarDrop in the discovery of new ways to combat superbugs.”

Dr Girinath Pillai, CEO at Zastra Innovations, Optibrium’s distribution partner in India, added: “We are very pleased to have been able to support Optibrium and Bugworks in establishing the license agreement. We will continue to ensure easy and fast access to StarDrop with our dedicated team for local on-call and on-site support.”

StarDrop is a comprehensive suite of integrated software with a highly visual and user-friendly interface. It enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the drug discovery process. Seamlessly connecting with other informatics methods and databases, StarDrop provides user-friendly access to resources, making project management quicker and simpler.

For further information on Optibrium and StarDrop, please visit www.optibrium.com/stardrop/, contact info@optibrium.com or call +44 1223 815900.

For further information on Zastra Innovations, please visit www.zastrain.com or contact info@zastrain.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005629/en/

CONTACT

Zyme Communications
Sarah Jeffery, +44 (0) 7771 730919
sarah.jeffery@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
  • New Data Shows Previously Allergic Children Still Able to Tolerate Peanut Four Years after Treatment with a Novel Immunotherapy Licensed by Prota Therapeutics
  • Mannatech Australia Makes the Morning Healthier with New Nutrient-Rich Coffee
  • CDISC Releases Therapeutic Area User Guide to Assist in Discovery of New Treatments for Prostate Cancer
  • 迪拜卫生署部署Masimo Patient SafetyNet™